Efficacy and safety of remimazolam besylate and ciprofol in painless gastrointestinal endoscopy in the elderly
Author Information
Author(s): Zhu Ziwei
Primary Institution: The Fourth Affiliated Hospital of Soochow University
Hypothesis
This study aimed to ascertain the efficacy and safety of remimazolam besylate and ciprofol in elderly patients undergoing painless gastrointestinal endoscopy.
Conclusion
Remimazolam besylate has better anesthetic and analgesic effects, more stable hemodynamics, less impact on cognitive function, and good safety in elderly patients undergoing painless gastrointestinal endoscopy compared to ciprofol.
Supporting Evidence
- Remimazolam besylate had a shorter anesthesia onset time and recovery time compared to ciprofol.
- The effective rate of analgesia was higher in the remimazolam group (96.77%) than in the ciprofol group (80.65%).
- Remimazolam besylate showed more stable hemodynamics during the procedure.
- MMSE scores indicated less impact on cognitive function in the remimazolam group.
Takeaway
This study found that a new medicine called remimazolam works better and is safer for older people during a special stomach test than an older medicine called ciprofol.
Methodology
Patients were randomly assigned to receive either remimazolam besylate or ciprofol for anesthesia during painless gastrointestinal endoscopy, and various effects were compared.
Limitations
The study did not consider the influence of educational level on MMSE scores, had a short follow-up period, and a relatively small sample size.
Participant Demographics
Elderly patients aged 60 and above with ASA classification I-II.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website